Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Website: nuvalent.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 3.4% (LTM)

Entry Point: Share price is 339.3% higher than minimum and 7.6% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders sold company shares on $51.7 mln (-0.822% of cap.)

Key Financials (Download financials)

Ticker: NUVL
Share price, USD:  (+2.7%)103.59
year average price 84.72  


year start price 85.68 2025-02-08

min close price 59.32 2025-04-08

max close price 111.99 2026-01-22

current price 103.59 2026-02-07
Common stocks: 64 605 308

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 6 692
Net Debt ($m): -658
EV (Enterprise Value): 6 034
Price to Book: 7.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-02-05prnewswire.com

Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12prnewswire.com

Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones

2025-12-22prnewswire.com

Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-16globenewswire.com

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

2025-11-26prnewswire.com

Nuvalent to Participate in the Piper Sandler 37th Annual Healthcare Conference

2025-11-18prnewswire.com

Nuvalent Announces Pricing of Public Offering of Common Stock

2025-11-17seekingalpha.com

Nuvalent, Inc. (NUVL) Discusses Topline Pivotal Data From ALKOVE-1 Trial of Neladalkib in ALK-Positive Non-Small Cell Lung Cancer Transcript

2025-11-17benzinga.com

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

2025-11-17prnewswire.com

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

2025-11-04seekingalpha.com

Nuvalent: Interesting Product, But Aggressive Valuation
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-14 2023-08-10 2023-05-11 2022-11-10
acceptedDate 2025-10-30 06:42:36 2025-08-07 06:40:22 2025-02-27 06:43:06 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27 2022-03-29 07:21:19 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 84M 81M 218M 61M 49M 39M 113M 30M 26M 22M 64M 15M 36M 15M
generalAndAdministrativeExpenses 29M 24M 63M 16M 16M 14M 36M 9M 8M 8M 22M 6M 10M 2M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 29M 24M 63M 16M 16M 14M 36M 9M 8M 8M 22M 6M 10M 2M
otherExpenses 0 0 0 0 0 0 0 0 0 5M 0 0 0 0
operatingExpenses 113M 105M 280M 76M 65M 53M 149M 39M 34M 30M 86M 20M 46M 17M
costAndExpenses 113M 105M 280M 76M 65M 53M 149M 39M 34M 30M 86M 20M 46M 17M
interestIncome 10M 11M 38M 9M 8M 8M 23M 5M 5M 0 0 0 0 0
interestExpense 0 0 0 0 0 8M 23M 5M 5M -5M 0 -672 000 0 0
depreciationAndAmortization 0 0 280M 0 0 53M 0 0 0 0 0 0 0 0
ebitda -122M -105M 0 -76M -65M -53M -126M -39M -34M -30M -86M -20M -46M -17M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -113M -105M -280M -76M -65M -53M -149M -39M -34M -30M -86M -20M -46M -17M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -10M 5M 20M -8M 8M 8M 23M 5M 5M 5M 4M 672 000 -521 000 2M
incomeBeforeTax -122M -100M -260M -84M -57M -44M -126M -34M -29M -25M -82M -20M -46M -15M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 132 000 145 000 764 000 40 000 170 000 -383 000 0 0 0 -5M 0 -672 000 0 0
netIncome -122M -100M -261M -84M -57M -44M -126M -34M -29M -20M -82M -19M -46M -15M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -1.7 -1.39 -3.93 -1.28 -0.88 -0.69 -2.17 -0.59 -0.51 -0.36 -1.65 -0.39 -2.13 -0.64
epsdiluted -1.7 -1.39 -1.28 -0.88 -0.69 -0.59 -0.51 -0.36 -0.39
weightedAverageShsOut 72M 72M 66M 66M 65M 64M 58M 57M 57M 57M 50M 48M 22M 23M
weightedAverageShsOutDil 72M 72M 66M 66M 65M 64M 58M 57M 57M 57M 50M 48M 22M 23M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-16 2022-03-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 38M 0 0 0 0
ebit -280M -126M -86M -46M -17M
nonOperatingIncomeExcludingInterest 0 -23M 0 0 0
netIncomeFromContinuingOperations -261M -126M -82M -46M -15M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -261M -126M -82M -46M -15M
epsDiluted -3.93 -2.17 -1.65 -2.13 -0.64

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-14 2023-08-10 2023-05-11 2022-11-10
acceptedDate 2025-10-30 06:42:36 2025-08-07 06:40:22 2025-02-27 06:43:06 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27 2022-03-29 07:21:19 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 116M 127M 146M 369M 78M 99M 335M 88M 71M 90M 242M 76M 69M 10M
shortTermInvestments 827M 878M 973M 799M 580M 593M 385M 325M 360M 360M 230M 164M 220M 0
cashAndShortTermInvestments 943M 1 006M 1 118M 1 168M 658M 692M 720M 413M 431M 450M 472M 240M 288M 10M
netReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentAssets 14M 14M 14M 11M 8M 8M 7M 7M 6M 6M 6M 5M 0 314 000
totalCurrentAssets 957M 1 020M 1 132M 1 180M 666M 699M 726M 420M 437M 456M 478M 245M 291M 11M
propertyPlantEquipmentNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 23M 21M 9M 9M 9M 9M 6M 5M 5M 5M 4M 4M 3M 0
totalNonCurrentAssets 23M 21M 9M 9M 9M 9M 6M 5M 5M 5M 4M 4M 3M 0
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 980M 1 041M 1 142M 1 189M 675M 708M 732M 425M 442M 461M 482M 250M 294M 11M
accountPayables 22M 13M 5M 16M 7M 13M 9M 10M 8M 6M 7M 5M 3M 1M
shortTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherCurrentLiabilities 67M 62M 0 35M 31M 20M 7M 19M 13M 11M 7M 8M 3M 3M
totalCurrentLiabilities 89M 75M 54M 51M 38M 33M 32M 29M 21M 17M 19M 13M 9M 4M
longTermDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 2M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 45M 26M 18M 17M 0 0 0 0 0 6M 0 -5M 0 35M
totalNonCurrentLiabilities 45M 26M 18M 17M 0 0 0 0 0 6M 7M 5M 3M 38M
otherLiabilities 0 0 0 0 0 0 0 0 0 -6M -7M -5M -3M 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 135M 101M 72M 68M 38M 33M 32M 29M 21M 17M 19M 13M 9M 42M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 8000 8000 8000 8000 7000 7000 7000 6000 6000 6000 6000 5000 5000 0
retainedEarnings -854M -731M -547M -472M -388M -331M -286M -248M -214M -185M -160M -134M -78M -32M
accumulatedOtherComprehensiveIncomeLoss 2M 1M -59 000 1M -2M -1M 31 000 -1M -2M -302 000 -494 000 -866 000 -228 000 -280 000
othertotalStockholdersEquity 1 697M 1 670M 1 592M 1 027M 1 007M 645M 637M 630M 371M
totalStockholdersEquity 845M 940M 1 070M 1 121M 637M 675M 701M 396M 421M 444M 463M 237M 285M -31M
totalEquity 845M 940M 1 070M 1 121M 637M 675M 701M 396M 421M 444M 463M 237M 285M -31M
totalLiabilitiesAndStockholdersEquity 980M 1 041M 1 189M 675M 708M 425M 442M 461M 250M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 980M 1 041M 1 142M 1 189M 675M 708M 732M 425M 442M 461M 482M 250M 294M 11M
totalInvestments 827M 878M 973M 799M 580M 593M 385M 325M 360M 360M 230M 164M 220M 0
totalDebt 0 0 0 0 0 0 0 0 0 0 0 0 0 2M
netDebt -116M -127M -146M -369M -78M -99M -335M -88M -71M -90M -242M -76M -69M -8M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-16 2022-03-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 0 0
otherReceivables 0 0 0 0 0
prepaids 0 0 0 3M 0
totalPayables 5M 9M 7M 3M 1M
otherPayables 0 0 0 0 0
accruedExpenses 49M 15M 5M 3M 535 000
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 617M 987M 624M 363M 842 000
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL NUVL
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-10-30 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-14 2023-08-10 2023-05-11 2022-11-10
acceptedDate 2025-10-30 06:42:36 2025-08-07 06:40:22 2025-02-27 06:43:06 2024-11-12 06:42:31 2024-08-08 06:46:28 2024-05-09 06:46:09 2024-02-27 06:42:43 2023-11-14 06:50:42 2023-08-10 06:49:05 2023-05-11 06:44:40 2023-03-16 06:44:09 2022-11-10 07:01:27 2022-03-29 07:21:19 2020-12-31 00:00:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -122M -100M -261M -84M -57M -44M -126M -34M -29M -25M -82M -20M -46M -15M
depreciationAndAmortization 0 0 0 0 0 0 0 0 0 -3M -373 000 0 215 000 0
deferredIncomeTax 0 0 0 0 0 0 0 0 0 0 -6M 0 -215 000 0
stockBasedCompensation 0 22M 61M 15M 0 14M 26M 7M 6M 5M 10M 3M 4M 729 000
changeInWorkingCapital 12M -2M 12M -2M 4M -2M 11M 6M 4M -2M 7M -1M 2M 1M
accountsReceivables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables 9M -13M -4M 8M -6M 4M 2M 2M 2M -672 000 4M 592 000 2M 529 000
otherWorkingCapital 3M 10M 16M -11M 10M -6M 9M 5M 2M 672 000 3M -2M 300 000 738 000
otherNonCashItems 40M 3M 3M 25M 12M 6M -10M -3M -3M 0 6M -3000 846 000 -2M
netCashProvidedByOperatingActivities -70M -77M -185M -46M -41M -36M -100M -23M -22M -24M -65M -18M -40M -15M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 0 0 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -178M -158M -1 025M -341M -89M -283M -459M -23M -82M -188M -213M -20M -221M 0
salesMaturitiesOfInvestments 232M 236M 451M 128M 105M 76M 316M 62M 83M 61M 202M 37M 1M 0
otherInvestingActivites 0 0 0 -1 -207M 38 400 0 0 0
netCashUsedForInvestingActivites 54M 77M -213M 16M -207M 38M 2M -127M 18M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 5M 6M 550M 4M 6M 1M 2M 619 000 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 -188 000 -156 000 -466 000 755 000 -364 000 -636 000 1M
netCashUsedProvidedByFinancingActivities 5M 6M 550M 4M 6M 2M 1M -17 000 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash -12M 7M -190M 292M -21M -237M 94M 18M -19M -152M 173M 398 000 58M 7M
cashAtEndOfPeriod 116M 127M 146M 369M 78M 99M 335M 88M 71M 90M 242M 76M 69M 10M
cashAtBeginningOfPeriod 127M 121M 335M 78M 99M 335M 242M 71M 90M 242M 69M 76M 10M 3M
operatingCashFlow -70M -77M -185M -46M -41M -36M -100M -23M -22M -24M -65M -18M -40M -15M
capitalExpenditure 0 0 0 0 0 0 0 0 0 0 0 0 0 0
freeCashFlow -70M -77M -185M -46M -41M -36M -100M -23M -22M -24M -65M -18M -40M -15M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2024-02-27 2023-03-16 2022-03-29 2020-12-31
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 0 0
netCashProvidedByInvestingActivities -574M -144M -11M -220M 0
netDebtIssuance 0 0 0 284 000 -250 000
longTermNetDebtIssuance 0 0 0 284 000 -250 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 570M 324M 249M 322M 23M
netCommonStockIssuance 570M 324M 249M 177M 0
commonStockIssuance 570M 324M 249M 177M 0
netPreferredStockIssuance 0 0 0 145M 23M
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -1M 13M 286 000 -4M 15 000
netCashProvidedByFinancingActivities 569M 337M 249M 318M 22M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

SEC forms

Show financial reports only

SEC form 8
2026-01-14 11:30 ET
Nuvalent, Inc. published news for 2025 q4
SEC form 8
2026-01-14 11:30 ET
Nuvalent, Inc. published news for 2025 q4
SEC form 8
2025-11-20 11:01 ET
Nuvalent, Inc. published news for 2025 q3
SEC form 8
2025-11-20 11:01 ET
Nuvalent, Inc. published news for 2025 q3
SEC form 8
2025-11-20 11:01 ET
Nuvalent, Inc. published news for 2025 q3
SEC form 8
2025-11-20 11:01 ET
Nuvalent, Inc. published news for 2025 q3
SEC form 10
2025-10-30 10:42 ET
Nuvalent, Inc. reported for 2025 q3
SEC form 8
2025-10-30 10:37 ET
Nuvalent, Inc. published news for 2025 q3
SEC form 8
2025-10-30 10:37 ET
Nuvalent, Inc. reported for 2025 q3
SEC form 10
2025-08-07 10:40 ET
Nuvalent, Inc. reported for 2025 q2
SEC form 8
2025-08-07 10:35 ET
Nuvalent, Inc. published news for 2025 q2
SEC form 8
2025-08-07 10:35 ET
Nuvalent, Inc. reported for 2025 q2
SEC form 10
2025-05-08 11:42 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 8
2025-05-08 11:36 ET
Nuvalent, Inc. published news for 2025 q1
SEC form 8
2025-05-08 11:36 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Nuvalent, Inc. reported for 2025 q1
SEC form 10
2025-02-27 11:43 ET
Nuvalent, Inc. reported for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Nuvalent, Inc. reported for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Nuvalent, Inc. published news for 2024 q4
SEC form 8
2025-02-27 00:00 ET
Nuvalent, Inc. reported for 2024 q4
SEC form 10
2024-11-12 06:42 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 8
2024-11-12 06:38 ET
Nuvalent, Inc. published news for 2024 q3
SEC form 8
2024-11-12 06:38 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 10
2024-11-12 00:00 ET
Nuvalent, Inc. reported for 2024 q3
SEC form 10
2024-08-08 06:46 ET
Nuvalent, Inc. reported for 2024 q2
SEC form 8
2024-08-08 06:41 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 8
2024-08-08 06:41 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Nuvalent, Inc. published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Nuvalent, Inc. reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Nuvalent, Inc. published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Nuvalent, Inc. published news for 2024 q1
SEC form 10
2024-02-27 06:42 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 10
2024-02-27 00:00 ET
Nuvalent, Inc. reported for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-02-27 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 8
2024-01-09 00:00 ET
Nuvalent, Inc. published news for 2023 q4
SEC form 10
2023-11-14 06:50 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 8
2023-11-14 06:45 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Nuvalent, Inc. reported for 2023 q3
SEC form 10
2023-08-10 06:49 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 6
2023-08-10 06:45 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Nuvalent, Inc. reported for 2023 q2
SEC form 6
2023-06-16 18:46 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 6
2023-06-16 16:08 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 10
2023-05-11 06:44 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 6
2023-05-11 06:39 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Nuvalent, Inc. reported for 2023 q1
SEC form 6
2023-04-28 16:13 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 6
2023-04-13 16:30 ET
Nuvalent, Inc. published news for 2023 q1
SEC form 10
2023-03-16 06:44 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 6
2023-03-16 06:36 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 10
2023-03-16 00:00 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 8
2023-03-16 00:00 ET
Nuvalent, Inc. reported for 2022 q4
SEC form 6
2023-03-10 20:38 ET
Nuvalent, Inc. published news for 2022 q4
SEC form 10
2022-11-10 07:01 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 6
2022-11-10 06:37 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 10
2022-11-10 00:00 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Nuvalent, Inc. reported for 2022 q3
SEC form 6
2022-11-07 18:24 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-11-01 17:19 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-10-28 06:05 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 6
2022-10-06 16:16 ET
Nuvalent, Inc. published news for 2022 q3
SEC form 10
2022-08-10 07:08 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 6
2022-08-10 06:39 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 10
2022-08-10 00:00 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 8
2022-08-10 00:00 ET
Nuvalent, Inc. reported for 2022 q2
SEC form 6
2022-06-21 16:30 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-06-21 16:14 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-05-19 16:36 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 10
2022-05-12 06:52 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 6
2022-05-12 06:45 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Nuvalent, Inc. reported for 2022 q1
SEC form 6
2022-04-29 16:07 ET
Nuvalent, Inc. published news for 2022 q1
SEC form 6
2022-03-31 07:07 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-03-31 06:48 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2022-03-29 07:21 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-03-29 06:58 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2022-03-29 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 8
2022-03-29 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-02-03 16:41 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-02-03 06:46 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 6
2022-01-07 06:40 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 8
2022-01-07 00:00 ET
Nuvalent, Inc. published news for 2021 q4
SEC form 10
2021-11-10 06:49 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 6
2021-11-10 06:44 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 10
2021-11-10 00:00 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Nuvalent, Inc. published news for 2021 q3
SEC form 10
2021-09-08 08:31 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-09-08 06:35 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 10
2021-09-08 00:00 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-08-04 18:05 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-08-02 16:06 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-30 17:27 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:42 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:42 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:38 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:36 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:35 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:34 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:34 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:33 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:33 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:31 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 21:30 ET
Nuvalent, Inc. published news for 2021 q2
SEC form 6
2021-07-28 18:58 ET
Nuvalent, Inc. published news for 2021 q2